Lars Kaiser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lars Kaiser has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Elena Ahrens
Harvard Medical School Boston MA USA
3 shared publications - Maximilian Sebastian Schaefer
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Massachusetts; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Duesseldorf, Germany
3 shared publications - Béla-Simon Paschold
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ulm, Ulm, Germany
2 shared publications - Dario von Wedel
Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Informatics, Berlin, Germany
2 shared publications Denys Shay
2 shared publicationsGuanqing Chen
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Center for Anesthesia Research Excellence, Beth Israel Deaconess Medical Center, Boston, Massachusetts
2 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Association of intraoperative dexamethasone administration with postoperative delirium and the role of hyperglycaemia: a retrospective cohort study
- 31 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Open AccessAssociation of intraoperative dexamethasone administration with postoperative delirium and the role of hyperglycaemia: a retrospective cohort study
- 4 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 597-610
Changes in Intraoperative Rocuronium Dosing after the Introduction of Sugammadex and Association with Postoperative Respiratory Complications: A Retrospective Cohort Study
Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.
- 4 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 597-610
Changes in Intraoperative Rocuronium Dosing after the Introduction of Sugammadex and Association with Postoperative Respiratory Complications: A Retrospective Cohort Study
Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.
- 6 July 2025
- Published by Wiley in Anaesthesia
Dose‐dependent relationship between intra‐operative ketamine administration and postoperative delirium: a retrospective cohort study
Summary: Introduction: Ketamine is used frequently as an adjunct for general anaesthesia, exerting analgesic and opioid‐sparing properties at lower doses and psychotomimetic effects at higher doses. All dose ranges may have effects on the incidence of postoperative delirium, but clinical trials have been equivocal. We hypothesised that intra‐operative low‐dose ketamine is associated with a lower risk of postoperative delirium.Methods: A total of 106,982 adult patients undergoing general anaesthesia for non‐cardiac, non‐neurosurgical and non‐transplant procedures between 2008 and 2024 were included. Primary exposure was the intra‐operative cumulative ketamine dose (mg.kg‐1 body weight) dichotomised into high vs. low‐dose, based on the median of the cohort. Primary outcome was postoperative delirium within 7 days, based on keyword‐based search strategy, manual chart review, Confusion Assessment Method recordings and International Classification of Diseases diagnostic codes. Multivariable logistic regression and fractional polynomial regression analyses to assess a potential nonlinear dose–response relationship were performed.Results: Postoperative delirium occurred in 2837 (2.7%) patients. In total, 12,199 (11.4%) patients received ketamine, with a median (IQR [range]) intra‐operative dose of 0.35 (0.25–0.52 [0.01–3.86]) mg.kg‐1. Compared with patients not receiving ketamine, a low dose (≤ 0.35 mg.kg‐1, 6109 patients) was associated with lower risks of postoperative delirium (adjusted odds ratio 0.74 (95%CI 0.59–0.89), adjusted risk difference ‐0.7% (95%CI ‐1.0 to ‐0.3%); p = 0.003). Higher doses of ketamine (> 0.35 mg.kg‐1, 6090 patients) did not affect the risk of postoperative delirium (adjusted odds ratio 1.00 (95%CI 0.85–1.18); p = 0.96). Fractional polynomial regression analyses indicated a U‐shaped dose–response relationship, with a minimum postoperative delirium risk at a cumulative ketamine dose of 0.25–0.34 mg.kg‐1.Discussion: Intra‐operative low‐dose ketamine was associated with a lower risk of postoperative delirium, while high doses did not influence the risk.
- 6 July 2025
- Published by Wiley in Anaesthesia
Dose‐dependent relationship between intra‐operative ketamine administration and postoperative delirium: a retrospective cohort study
Summary: Introduction: Ketamine is used frequently as an adjunct for general anaesthesia, exerting analgesic and opioid‐sparing properties at lower doses and psychotomimetic effects at higher doses. All dose ranges may have effects on the incidence of postoperative delirium, but clinical trials have been equivocal. We hypothesised that intra‐operative low‐dose ketamine is associated with a lower risk of postoperative delirium.Methods: A total of 106,982 adult patients undergoing general anaesthesia for non‐cardiac, non‐neurosurgical and non‐transplant procedures between 2008 and 2024 were included. Primary exposure was the intra‐operative cumulative ketamine dose (mg.kg‐1 body weight) dichotomised into high vs. low‐dose, based on the median of the cohort. Primary outcome was postoperative delirium within 7 days, based on keyword‐based search strategy, manual chart review, Confusion Assessment Method recordings and International Classification of Diseases diagnostic codes. Multivariable logistic regression and fractional polynomial regression analyses to assess a potential nonlinear dose–response relationship were performed.Results: Postoperative delirium occurred in 2837 (2.7%) patients. In total, 12,199 (11.4%) patients received ketamine, with a median (IQR [range]) intra‐operative dose of 0.35 (0.25–0.52 [0.01–3.86]) mg.kg‐1. Compared with patients not receiving ketamine, a low dose (≤ 0.35 mg.kg‐1, 6109 patients) was associated with lower risks of postoperative delirium (adjusted odds ratio 0.74 (95%CI 0.59–0.89), adjusted risk difference ‐0.7% (95%CI ‐1.0 to ‐0.3%); p = 0.003). Higher doses of ketamine (> 0.35 mg.kg‐1, 6090 patients) did not affect the risk of postoperative delirium (adjusted odds ratio 1.00 (95%CI 0.85–1.18); p = 0.96). Fractional polynomial regression analyses indicated a U‐shaped dose–response relationship, with a minimum postoperative delirium risk at a cumulative ketamine dose of 0.25–0.34 mg.kg‐1.Discussion: Intra‐operative low‐dose ketamine was associated with a lower risk of postoperative delirium, while high doses did not influence the risk.